Catalog No.
EVV15105
Expression system
Mammalian Cells
Species
Epstein-Barr virus (strain B95-8) (HHV-4) (Human herpesvirus 4)
Protein length
Met361-Tyr674
Predicted molecular weight
37.66 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
P03231
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Envelope glycoprotein H, gH, gH, BXLF2
Eph Receptor Tyrosine Kinases Are Functional Entry Receptors for Murine Gammaherpesvirus 68., PMID:40501621
Anti-viral CD8 central memory veto cells as a new platform for CAR T cell therapy., PMID:40448965
AI-Driven Drug Target Screening Platform Identified Oncogene CACNA2D1 Activated by Enhancer Infestation in Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma., PMID:40429844
A Liposome-Based Nanoparticle Vaccine Induces Effective Immunity Against EBV Infection., PMID:40338258
High IgG titers against EBV glycoprotein 42 correlate with lower risk of nasopharyngeal carcinoma., PMID:39959976
Interpreting the role of epigallocatechin-3-gallate in Epstein-Barr virus infection-mediated neuronal diseases., PMID:39849283
In-depth analysis of serum antibodies against Epstein-Barr virus lifecycle proteins, and EBNA1, ANO2, GlialCAM and CRYAB peptides in patients with multiple sclerosis., PMID:39742283
CD4 T cells restricted to DRB1*15:01 recognize two Epstein-Barr virus glycoproteins capable of intracellular antigen presentation., PMID:39432795
TianTan vaccinia virus-based EBV vaccines targeting both latent and lytic antigens elicits potent immunity against lethal EBV challenge in humanized mice., PMID:39387189
GB and gH/gL fusion machinery: a promising target for vaccines to prevent Epstein-Barr virus infection., PMID:39020055
A gH/gL-encoding replicon vaccine elicits neutralizing antibodies that protect humanized mice against EBV challenge., PMID:38926438
Vaccination with nanoparticles displaying gH/gL from Epstein-Barr virus elicits limited cross-protection against rhesus lymphocryptovirus., PMID:38781964
Epstein-Barr virus gp42 antibodies reveal sites of vulnerability for receptor binding and fusion to B cells., PMID:38479361
Severe hematopoietic stem cell inflammation compromises chronic granulomatous disease gene therapy., PMID:36706754
Urgency and necessity of Epstein-Barr virus prophylactic vaccines., PMID:36494369
Epstein-Barr virus gH/gL has multiple sites of vulnerability for virus neutralization and fusion inhibition., PMID:36306784
Cholesterol not particle concentration mediates the atherogenic risk conferred by apolipoprotein B particles: a Mendelian randomization analysis., PMID:36125206
Immunization with a self-assembling nanoparticle vaccine displaying EBV gH/gL protects humanized mice against lethal viral challenge., PMID:35705092
A novel high throughput assay to quantify Epstein-Barr virus neutralizing antibody activity against B-cell and epithelial cell infections for vaccine and therapeutic developments., PMID:35577627
A bivalent Epstein-Barr virus vaccine induces neutralizing antibodies that block infection and confer immunity in humanized mice., PMID:35507671
Four Decades of Prophylactic EBV Vaccine Research: A Systematic Review and Historical Perspective., PMID:35493498
A Neutralizing Antibody Targeting gH Provides Potent Protection against EBV Challenge In Vivo., PMID:35348362
Antibody Generation and Immunogenicity Analysis of EBV gp42 N-Terminal Region., PMID:34960650
Potential entry receptors for human γ-herpesvirus into epithelial cells: A plausible therapeutic target for viral infections., PMID:34800753
A potent and protective human neutralizing antibody targeting a novel vulnerable site of Epstein-Barr virus., PMID:34785638
Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases., PMID:34691042
Immunization with Epstein-Barr Virus Core Fusion Machinery Envelope Proteins Elicit High Titers of Neutralizing Activities and Protect Humanized Mice from Lethal Dose EBV Challenge., PMID:33808755
Plxdc family members are novel receptors for the rhesus monkey rhadinovirus (RRV)., PMID:33657166
In silico analysis of antiviral phytochemicals efficacy against Epstein-Barr virus glycoprotein H., PMID:33438528
Lifelong Reduction in LDL (Low-Density Lipoprotein) Cholesterol due to a Gain-of-Function Mutation in LDLR., PMID:33315477
Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma., PMID:33268566
Analysis of latent T-cell epitopes in Epstein-Barr virus isolated from extranodal nasal-type natural killer/T-cell lymphoma in Taiwanese population., PMID:33242451
Molecular basis of EphA2 recognition by gHgL from gammaherpesviruses., PMID:33235207
Laron Syndrome Research Paves the Way for New Insights in Oncological Investigation., PMID:33182502
Maternal Epstein-Barr Virus-Specific Antibodies and Risk of Infection in Ugandan Infants., PMID:33095855
The structural basis of herpesvirus entry., PMID:33087881
Epstein-Barr Virus gH/gL and Kaposi's Sarcoma-Associated Herpesvirus gH/gL Bind to Different Sites on EphA2 To Trigger Fusion., PMID:32847853
HLA-DPB1 and Epstein-Barr virus gp42 protein jointly contribute to the development of Hodgkin lymphoma., PMID:35117807
A Pentavalent Epstein-Barr Virus-Like Particle Vaccine Elicits High Titers of Neutralizing Antibodies against Epstein-Barr Virus Infection in Immunized Rabbits., PMID:32268575
Eph receptors: the bridge linking host and virus., PMID:31893311
EBNA1 IgM-Based Discrimination Between Rheumatoid Arthritis Patients, Systemic Lupus Erythematosus Patients and Healthy Controls., PMID:31544841
Gammaherpesvirus entry and fusion: A tale how two human pathogenic viruses enter their host cells., PMID:31439152
Identification of multiple potent neutralizing and non-neutralizing antibodies against Epstein-Barr virus gp350 protein with potential for clinical application and as reagents for mapping immunodominant epitopes., PMID:31377598
Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells., PMID:30979688
Ephrin Receptor A4 is a New Kaposi's Sarcoma-Associated Herpesvirus Virus Entry Receptor., PMID:30782663
Immunoinformatic and systems biology approaches to predict and validate peptide vaccines against Epstein-Barr virus (EBV)., PMID:30679646
Targeted Diet Modification Reduces Multiple Sclerosis-like Disease in Adult Marmoset Monkeys from an Outbred Colony., PMID:30341184
Co-localization of and interaction between duck enteritis virus glycoprotein H and L., PMID:30157854
An Antibody Targeting the Fusion Machinery Neutralizes Dual-Tropic Infection and Defines a Site of Vulnerability on Epstein-Barr Virus., PMID:29669253
Antibodies to a strain-specific citrullinated Epstein-Barr virus peptide diagnoses rheumatoid arthritis., PMID:29487382
For research use only. Not for human or drug use.
